Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 5/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509478 | 0.89 | HSD11B1 (0.50) | HSD11B1PRCPHCRTR1HCRTR2 | |
| SCHEMBL2775481 | 0.82 | HCRTR1 (0.46) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL2777207 | 0.82 | PRCP (0.51) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL2777787 | 0.82 | HCRTR1 (0.46) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL12422955 | 0.80 | HCRTR1 (0.40) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL2778769 | 0.80 | HCRTR1 (0.46) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL2775716 | 0.80 | PRCP (0.49) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL1836139 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL2778773 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL12798462 | 0.79 | PRCP (0.53) | PRCPHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243257-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | HSD11B1 3103/4885PRCP 2425/4885HCRTR1 1341/4885 |
| US-20130157997-A1 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BRI3BP, BLVRB, BRIX1 | HSD11B1 3103/4885PRCP 2425/4885HCRTR1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.